Dermatologists may recommend non-steroidal options—such as topical calcineurin inhibitors (TCIs), phosphodiesterase inhibitors (Eucrisa), or janus kinase inhibitors (Opzelura)—for eczema ...

Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy ...